Publications by authors named "Cristian Rodriguez-Aguayo"

100Publications

Aptamers: Novel Therapeutics and Potential Role in Neuro-Oncology.

Cancers (Basel) 2020 Oct 9;12(10). Epub 2020 Oct 9.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12102889DOI Listing
October 2020

Back to the Future: Rethinking the Great Potential of lncRNA for Optimizing Chemotherapeutic Response in Ovarian Cancer.

Cancers (Basel) 2020 Aug 25;12(9). Epub 2020 Aug 25.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12092406DOI Listing
August 2020

NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.

Mol Cancer Ther 2020 08 4;19(8):1727-1735. Epub 2020 Jun 4.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-19-0977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415525PMC
August 2020

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.

Int J Mol Sci 2020 Apr 23;21(8). Epub 2020 Apr 23.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21082974DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215326PMC
April 2020

Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112].

EBioMedicine 2020 Feb 20;52:102630. Epub 2020 Jan 20.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Road, Unit 1950, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2020.102630DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974767PMC
February 2020

miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.

Cell Rep 2019 12;29(13):4389-4406.e10

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.11.085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380555PMC
December 2019

Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

RNA Biol 2020 Nov 17;17(11):1523-1534. Epub 2019 Dec 17.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center , Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15476286.2019.1702283DOI Listing
November 2020

Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease.

Cell Metab 2019 06 28;29(6):1274-1290.e9. Epub 2019 Mar 28.

Department of Physiology and Biophysics, Baylor College of Medicine, Houston, TX 77030, USA; Huffington Center on Aging, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cmet.2019.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657508PMC
June 2019

PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

EBioMedicine 2019 Feb 14;40:290-304. Epub 2019 Jan 14.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.11.045DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411965PMC
February 2019

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.

Mol Ther Nucleic Acids 2019 Mar 13;14:301-317. Epub 2018 Dec 13.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2018.11.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348737PMC
March 2019

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.

EBioMedicine 2018 Dec 25;38:100-112. Epub 2018 Nov 25.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964183049
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2018.11.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306310PMC
December 2018

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.

Mol Ther Nucleic Acids 2017 Dec 5;9:251-262. Epub 2017 Jul 5.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2017.06.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675720PMC
December 2017

RNA interference-based therapy and its delivery systems.

Cancer Metastasis Rev 2018 03;37(1):107-124

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10555-017-9717-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898634PMC
March 2018

MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.

Cancer Res 2018 01 27;78(1):64-74. Epub 2017 Nov 27.

Abramson Family Cancer Research Institute, Abramson Cancer Center and Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993051PMC
January 2018

Chitosan Nanoparticles for miRNA Delivery.

Methods Mol Biol 2017 ;1632:219-230

Center for RNA Interference and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7138-1_14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423176PMC
April 2018

miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.

Sci Rep 2017 06 15;7(1):3614. Epub 2017 Jun 15.

Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-03972-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472620PMC
June 2017

Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer.

Clin Cancer Res 2017 Sep 13;23(18):5611-5621. Epub 2017 Jun 13.

Department of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-3272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600833PMC
September 2017

Exosomes: From Garbage Bins to Promising Therapeutic Targets.

Int J Mol Sci 2017 Mar 2;18(3). Epub 2017 Mar 2.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms18030538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372554PMC
March 2017

Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.

Mol Cancer Ther 2017 05 21;16(5):966-976. Epub 2017 Feb 21.

Department of Chemical Engineering, University of Puerto Rico-Mayagüez, Mayagüez, Puerto Rico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0519DOI Listing
May 2017

Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.

Cell Rep 2016 11;17(6):1621-1631

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, MDACC, Houston, TX 77030, USA; Department of Cancer Biology, MDACC, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2016.10.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123842PMC
November 2016

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.

Cancer Cell 2016 06;29(6):874-888

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.04.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908836PMC
June 2016

Role of Increased n-acetylaspartate Levels in Cancer.

J Natl Cancer Inst 2016 Jan 26;108(6):djv426. Epub 2016 Jan 26.

Departments of Gynecologic Oncology and Reproductive Medicine (BZ, RAP, RR, TM, ASN, HJD, WH, CI, SYW, KMG, SP, LSM, AMN, GAP, AKS), Cancer Systems Imaging (NMZ, CRM, PKB), Biostatistics (MG), Cancer Medicine (CVP), Center for RNA Interference and Non-Coding RNA (CI, LSM, CRA, GLB, AKS), Cancer Biology (YS, MBE, GLB, AKS), Experimental Therapeutics (CRA, GLB), Bioinformatics and Computational Biology (YW, KAB), Melanoma Medical Oncology (MAD), and Pathology (JL), University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Nanomedicine and Bioengineering, UT Health, Houston, TX (GLB, AKS); Departments of Psychology, Urology, and Obstetrics and Gynecology, the University of Iowa, Iowa City, IA (SKL); Laboratory for Systems Biology of Human Diseases (LY, JB, AA, DN), Department of Chemical and Biomolecular Engineering (LY, JB, AA, DN), and Department of Bioengineering (DN), Rice University, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849357PMC
January 2016

Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.

Cell Rep 2015 Dec 10;13(11):2395-2402. Epub 2015 Dec 10.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.11.047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4691557PMC
December 2015

Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.

Hepatology 2016 Mar 14;63(3):864-79. Epub 2016 Jan 14.

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.28367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4764447PMC
March 2016

Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.

Clin Cancer Res 2016 Apr 18;22(7):1713-24. Epub 2015 Nov 18.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas. Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818718PMC
April 2016

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.

J Natl Cancer Inst 2015 Jul 20;107(7). Epub 2015 May 20.

: Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).

View Article

Download full-text PDF

Source
http://academic.oup.com/jnci/article/doi/10.1093/jnci/djv108
Publisher Site
http://dx.doi.org/10.1093/jnci/djv108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554255PMC
July 2015

TP53 loss creates therapeutic vulnerability in colorectal cancer.

Nature 2015 Apr 22;520(7549):697-701. Epub 2015 Apr 22.

1] Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Center for RNA Interference and Non-coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14418DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417759PMC
April 2015

Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.

Clin Cancer Res 2015 May 16;21(9):2127-37. Epub 2015 Jan 16.

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for RNAi and Non-coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/01/
Web Search
http://clincancerres.aacrjournals.org/content/early/2015/03/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-2279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417466PMC
May 2015

miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.

Nat Commun 2014 Dec 5;5:5671. Epub 2014 Dec 5.

1] Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA [2] Cancer Biology and Genes &Development Programs, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6671DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377070PMC
December 2014

Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.

Nat Commun 2014 Oct 29;5:5202. Epub 2014 Oct 29.

1] Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [2] Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA [3] Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215647PMC
October 2014

Therapeutic silencing of KRAS using systemically delivered siRNAs.

Mol Cancer Ther 2014 Dec 3;13(12):2876-85. Epub 2014 Oct 3.

Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416486PMC
December 2014

MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.

J Pathol 2015 Jan 6;235(1):25-36. Epub 2014 Nov 6.

Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4443DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268369PMC
January 2015

Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Cancer Cell 2014 Jul;26(1):77-91

Department of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.05.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100212PMC
July 2014

Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue.

J Liposome Res 2014 Sep 20;24(3):182-90. Epub 2014 Jan 20.

Department of Atherosclerosis Research, Texas Heart Institute , Houston, TX , USA .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08982104.2013.863208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431645PMC
September 2014

EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.

Carcinogenesis 2014 May 30;35(5):1100-9. Epub 2013 Dec 30.

Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, SC 29425, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgt489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004201PMC
May 2014

FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.

Carcinogenesis 2012 Oct 10;33(10):1843-53. Epub 2012 May 10.

Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgs167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529559PMC
October 2012

Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

Clin Cancer Res 2011 Jun 21;17(11):3716-26. Epub 2011 Apr 21.

University of Puerto Rico Comprehensive Cancer Center; Department of Biochemistry, University of Puerto Rico, Medical Science Campus, San Juan, Puerto Rico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108184PMC
June 2011